Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients

S Jeong, IW Kim, KH Oh, N Han, KW Joo… - Drug Design …, 2016 - Taylor & Francis
Background Secondary hyperparathyroidism (SHPT) is one of the major risk factors of
morbidity and mortality in end-stage renal disease. Cinacalcet effectively controls SHPT …
被引用次数：21 相关文章

Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients.

S Jeong, IW Kim, KH Oh, N Han, KW Joo… - Drug Design …, 2016 - europepmc.org
Background Secondary hyperparathyroidism (SHPT) is one of the major risk factors of
morbidity and mortality in end-stage renal disease. Cinacalcet effectively controls SHPT …

Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients

S Jeong, IW Kim, KH Oh, N Han… - Drug design …, 2016 - pubmed.ncbi.nlm.nih.gov
Background Secondary hyperparathyroidism (SHPT) is one of the major risk factors of
morbidity and mortality in end-stage renal disease. Cinacalcet effectively controls SHPT …
[PDF] semanticscholar.org

[PDF][PDF] Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients

K Oh, KW Joo, JM Oh - Drug Design, Development and …, 2016 - pdfs.semanticscholar.org
Background: Secondary hyperparathyroidism (SHPT) is one of the major risk factors of
morbidity and mortality in end-stage renal disease. Cinacalcet effectively controls SHPT …

Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients

S Jeong, IW Kim, KH Oh, N Han… - Drug Design …, 2016 - search.proquest.com
Background: Secondary hyperparathyroidism (SHPT) is one of the major risk factors of
morbidity and mortality in end-stage renal disease. Cinacalcet effectively controls SHPT …
[PDF] scienceopen.com

[PDF][PDF] Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients

K Oh, KW Joo, JM Oh - Drug Design, Development and Therapy, 2016 - scienceopen.com
Background: Secondary hyperparathyroidism (SHPT) is one of the major risk factors of
morbidity and mortality in end-stage renal disease. Cinacalcet effectively controls SHPT …

Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients

S Jeong, IW Kim, KH Oh, N Han, KW Joo… - Drug Design …, 2016 - go.gale.com
Background: Secondary hyperparathyroidism (SHPT) is one of the major risk factors of
morbidity and mortality in end-stage renal disease. Cinacalcet effectively controls SHPT …

Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients

S Jeong, IW Kim, KH Oh, N Han, KW Joo… - Drug Design …, 2016 - dovepress.com
Background: Secondary hyperparathyroidism (SHPT) is one of the major risk factors of
morbidity and mortality in end-stage renal disease. Cinacalcet effectively controls SHPT …

Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients

S Jeong, IW Kim, KH Oh, N Han… - Drug Design …, 2016 - snucm.elsevierpure.com
Background: Secondary hyperparathyroidism (SHPT) is one of the major risk factors of
morbidity and mortality in end-stage renal disease. Cinacalcet effectively controls SHPT …
[HTML] nih.gov

[HTML][HTML] Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients

S Jeong, IW Kim, KH Oh, N Han, KW Joo… - Drug Design …, 2016 - ncbi.nlm.nih.gov
Background Secondary hyperparathyroidism (SHPT) is one of the major risk factors of
morbidity and mortality in end-stage renal disease. Cinacalcet effectively controls SHPT …